Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06281210

Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery

This single arm study aims to evaluate the efficacy and safety of a non-surgical approach, consisting of radiotherapy (RT) alone, for patients who have achieved a complete pathological response (pCR) following neoadjuvant chemotherapy (NACT). The study design involves the histological confirmation of pCR using vacuum-assisted biopsy (VABB) or vacuum-assisted excision (VAE) guided by ultrasound. The primary objective is to demonstrate that the non-surgical, RT-only treatment and follow-up approach is not inferior to the traditional surgical approach in patients with pCR after NACT.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Istituto di Candiolo IRCCS, Candiolo, Turin, Italy

Loading trial locations.

About this study

Neoadjuvant chemotherapy (NACT) in breast cancer is considered the "gold standard" for the treatment of locally advanced and inoperable malignancies.

In recent years, in view of the evidence gathered, it has also become a conventional treatment alternative for patients with operable disease who are possible candidates for adjuvant chemotherapy. NACT thus aims to reduce mortality and increase surgical options, while at the same time allowing in vivo chemosensitivity testing. In view of this, NACT represents the ideal setting for clinical and translational research, which nowadays also has to address the question of future treatment options.

It is indeed a source of lively debate whether chemotherapy should be considered the only possible treatment option for the patient.

This study falls into this context, the innovative aim of which is to demonstrate histologically with the use of VABB, the complete pathological response (pCR) and to avoid surgery.

The main aim of this study is to show that a non-surgical, radiotherapy-only treatment and follow-up approach is not inferior to a surgical approach for patients who have shown complete pathological response (pCR) following neoadjuvant chemotherapy (NACT), as confirmed through histological analysis of imaging-guided sampling.

Histology will be performed by sampling 4 grams of tissue by vacuum-assisted biopsy (VABB) or vacuum-assisted excision (VAE) by ultrasound guidance (on breast marker).

The hypothesis of the study is that the VAE/VABB will be used in patients with pCR at post-NACT imaging to demonstrate the absence of disease in the previous tumour bed and, accordingly, that the use of VAE/VABB with negative histology would lead to a gold standard of treatment without surgical overtreatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age> 18 years
  • infiltrating breast carcinoma, non-special histotype, triple negative or HER2 +, T1-T2 N0
  • single lesion
  • neo-adjuvant chemotherapy treatment for at least 12 weeks according to clinical practice
  • conservative surgery proposal
  • M0
  • tumour bed identified by breast markers placed in pre NACT by radiologist

Exclusion criteria

  • Bilateral or multicentric tumour
  • Presence of microcalcifications visualised on mammography
  • Presence of associated DCIS
  • Positive history of previous breast cancer
  • Positive history of medical or psychiatric conditions preventing adherence to the protocol
  • High risk patient

Treatment and study plan

Omission of surgical treatment

Procedure

Omission of surgery in patients with pCR after neoadjuvant chemotherapy and negative VABB biopsy

Primary outcomes

  1. Event-free survival

    Time frame: 5 years

    Absence of disease recurrence or progression, second primary tumor, or death

Secondary outcomes

  1. Positive predictive value of MRI

    Time frame: 6 months

    Evaluation of the accuracy of breast MRI in predicting pCR following NACT

  2. Contrast-Enhanced Mammography (CEM) positive predictive value

    Time frame: 6 months

    Evaluation of the accuracy of breast CEM in predicting pCR following NACT

Study contacts

Contact information is provided by the study sponsor or research team.

Elisabetta Rossi, MD

CONTACT

[email protected]

+39-0294372191

Sponsors and collaborators

Lead sponsor

European Institute of Oncology

Other

Registry information

Official study title

Non-inferiority Study in Patients With Complete Pathological Response After Neoadjuvant Chemotherapy and Negative VABB Biopsy Undergoing RT Alone, Omitting Surgical Treatment

Acronym: BETTY-CRASY

Important dates

Study start
2023
Primary completion
2028
Study completion
2028
First posted
Feb 28, 2024
Registry last updated
Feb 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.